Real-Life Use of Tocilizumab in the Treatment of Severe COVID-19 Pneumonia

Table 2

Comorbidities of patients receiving TCZ.

	Survived (n = 116)	Deceased (n = 9)	value	Improved (n = 109)	Not improved (n = 16)	value
Hypertension	41	6	0.79	38	9	0.165
Diabetes	48	7	0.42	46	9	0.419
Dyslipidemia	23	3	0.392	22	4	0.742
Pulmonary disease	9	1	0.54	8	2	0.615
Obesity	57	4	0.791	54	7	1.00
Cardiovascular disease	6	4	0.002	5	5	0.003
Renal insufficiency	1	2	0.013	0	3	0.002
Smoking	10	0	1.00	9	1	1.00
Others	26	6	0.009	23	9	0.005